Aurobindo Pharma announced that it has secured tentative approval from US Food and Drug Administration (USFDA) for Emtricitabine and Tenofovir Disoproxil Fumarate 200-mg/300-mg tablets under the President's Emergency Plan For AIDS Relief (PEPFAR).

Emtricitabine and Tenofovir Disoproxil Fumarate tabs, which come under the Anti-Retroviral (ARV) segment, are the generic version of Gilead Science Inc.'s HIV drug Truvada tablets.

Truvada is prescribed together with other antiretroviral agents to put control over HIV -1 infection in adults.

Presently, Aurobindo has 95 ANDA approvals from the USFDA that includes 68 final approvals and 27 tentative approvals.

The company stock, on Tuesday (March 31) marked its closure at Rs189.90, after making a gain of Rs 15.75 (9.04%) on the Bombay Stock Exchange (BSE). The stock hit an intraday high of Rs 200 and low of Rs 172.65.

The share price has seen a 52-week high of Rs 355 and a low of Rs 101.60 on BSE. Current EPS & P/E ratio stood at 41.66 and 4.56 respectively. 

The total traded quantity was 130708 compared to 2 week average of 40451.